Join to View Full Profile
1441 Catlin WayDresher, PA 19025
Phone+1 610-203-9328
Fax+1 866-305-6063
Are you Dr. Leopold?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lance Leopold, MD is an oncologist in Dresher, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1993- Temple University HospitalResidency, Internal Medicine, 1987 - 1990
Lewis Katz School of Medicine at Temple UniversityClass of 1987
Certifications & Licensure
PA State Medical License 1989 - 2026
Publications & Presentations
PubMed
- Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.Wilma Barcellini, Fabrizio Pane, Andrea Patriarca, Irina Murakhovskaya, Louis Terriou
American Journal of Hematology. 2024-12-01 - 2 citationsKEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced ...Noboru Yamamoto, Miyako Satouchi, Toshihiko Doi, Yutaka Fujiwara, Noriko Yanagitani
Investigational New Drugs. 2024-06-01 - 10 citationsExploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase...Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield
Journal for Immunotherapy of Cancer. 2022-03-01
Press Mentions
Incyte and Mirati Therapeutics Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsNovember 7th, 2022- Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)June 24th, 2021
- Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)February 26th, 2021
- Join now to see all
